Editorial Staff

How did COVID impact Massachusetts’ long-term care facilities?

/in , , , , , , , , /by Editorial Staff
Share on Facebook
Share on Twitter
Share on
LinkedIn
+

In April 2021, the Department of Public Health (DPH) removed from the COVID-19 Response Reporting Dashboard its former count of long-term care deaths, which was then greater than 9,000 – more than half of all reported COVID deaths at that time.  In place of the count of long-term care deaths was a vague reference to various separate reports, one of which contained a total number of eldercare deaths that was thousands lower than the previously displayed number.  

Pioneer reported this abrupt and substantial change in its May 2021 white paper, “A Brighter Dashboard: State Should Cut Confusion and Clarify Eldercare Cases and Deaths.”  The paper asked, understandably, for a clear explanation:  What counting methodology produced the 9,000-plus figure?  And, if thousands of those deaths are no longer considered long-term care deaths, what are representative examples of such deaths? Addressing this question would help the public understand what was removed from the former total.

Pioneer pressed the Executive Office of Health and Human Services and DPH for such an explanation orally in virtual meetings and in writing through 2021, and was unsuccessful in those efforts.  Subsequently, Pioneer has filed this Public Records Act request.  How COVID impacted Massachusetts’ long-term care facilities is a matter of obvious importance, both on principle (the public has a right to know the facts), and for purposes of evaluating – and where possible improving – public policy.  The state’s amendment of its long-term care death count may have been appropriate – but the public has the right to evaluate that question, and cannot do so absent a better explanation of what happened and why.

Read Public Records Request

Get Our COVID-19 News, Tips & Resources!

  • This field is for validation purposes and should be left unchanged.

Related Content:

Sunshine Week 2020 – When Government Transparency Is More Important Than Ever

0 Comments
/
COVID-19 has overshadowed what was supposed to be Sunshine Week, but vigilance on behalf of open government is even more crucial during times like these, when the public has limited access. But government transparency is important at all times. Each year during Sunshine Week, Pioneer reviews some of its recent work to increase public accountability in Massachusetts government.

Pioneer Institute & COVID-19

Message from Jim Stergios sharing important steps and work we at Pioneer will be undertaking during the COVID-19 pandemic, to continue to provide quality programming, research, videos, podcasts, and social media content, and serve as a resource for media and the public, with a focus on issues such as telecommuting and telemedicine, online learning and homeschooling options, and innovation in the life sciences.

Pioneer Poll: MA Healthcare Consumers Overwhelmingly Want Price Information on Services, but Few Know How to Get It

A new Pioneer poll shows seven out of ten Massachusetts workers who get their health insurance through their employers want to know the price of a healthcare procedure before they obtain it, but most of them do not how to obtain such information, even though information is already available through their insurers’ cost estimator tools.

Pioneer Institute to Present Results of New Consumer Poll Monday at State House Healthcare Price Transparency Event

BOSTON – Pioneer Institute will present the results of a new…

Making Healthcare Prices Accessible

Today, Pioneer Institute filed a Public Comment with the federal…

Study Finds Patient Cost for MRI Largely Unrelated to Overall Price or Insurer Contribution at 14 MA Hospitals

Read coverage of this report in WCVB-TV, Boston Herald, the Boston…

Kudos To CHIA On Major Step Toward Greater Healthcare Price Transparency

Pioneer applauds the Center for Health Information and Analysis…

Report Recommends Alternatives to Drug Pricing Transparency Legislation

0 Comments
/
Value-based reimbursement, focus on middlemen in drug distribution…